Helena Carreira1, Helen Strongman1, Maria Peppa2,3, Helen I McDonald2,3, Isabel Dos-Santos-Silva1, Susannah Stanway4, Liam Smeeth1, Krishnan Bhaskaran1. 1. Department of Non-communicable Disease Epidemiology, London School of Hygiene and Tropical Medicine, Keppel Street, London WC1 7HT, United Kingdom. 2. Department of Infectious Disease Epidemiology, London School of Hygiene and Tropical Medicine, Keppel Street, London WC1 7HT, United Kingdom. 3. Health Protection Research Unit in Immunisation, National Institute for Health Research, United Kingdom. 4. Department of Medicine, The Royal Marsden NHS Foundation Trust, London and Surrey, United Kingdom.
Abstract
BACKGROUND: People with active cancer are recognised as at risk of COVID-19 complications, but it is unclear whether the much larger population of cancer survivors is at elevated risk. We aimed to address this by comparing cancer survivors and cancer-free controls for (i) prevalence of comorbidities considered risk factors for COVID-19; and (ii) risk of severe influenza, as a marker of susceptibility to severe outcomes from epidemic respiratory viruses. METHODS: We included survivors (≥1 year) of the 20 most common cancers, and age, sex and general practice-matched cancer-free controls, derived from English primary care data linked to cancer registrations, hospital admissions and death registrations. Comorbidity prevalences were calculated 1 and 5 years from cancer diagnosis. Risk of hospitalisation or death due to influenza was compared using Cox models adjusted for baseline demographics and comorbidities. FINDINGS: 108,215 cancer survivors and 523,541 cancer-free controls were included. Cancer survivors had more diabetes, asthma, other respiratory, cardiac, neurological, renal, and liver diseases, and less obesity, compared with controls, but there was variation by cancer site. There were 205 influenza hospitalisations/deaths, with cancer survivors at higher risk than controls (adjusted HR 2.78, 95% CI 2.04-3.80). Haematological cancer survivors had large elevated risks persisting for >10 years (HR overall 15.17, 7.84-29.35; HR >10 years from cancer diagnosis 10.06, 2.47-40.93). Survivors of other cancers had evidence of raised risk up to 5 years from cancer diagnosis only (HR >5 years 2.22, 1.31-3.74). INTERPRETATION: Risks of severe COVID-19 outcomes are likely to be elevated in cancer survivors. This should be taken into account in policies targeted at clinical risk groups, and vaccination for both influenza, and, when available, COVID-19, should be encouraged in cancer survivors.
BACKGROUND: People with active cancer are recognised as at risk of COVID-19 complications, but it is unclear whether the much larger population of cancer survivors is at elevated risk. We aimed to address this by comparing cancer survivors and cancer-free controls for (i) prevalence of comorbidities considered risk factors for COVID-19; and (ii) risk of severe influenza, as a marker of susceptibility to severe outcomes from epidemic respiratory viruses. METHODS: We included survivors (≥1 year) of the 20 most common cancers, and age, sex and general practice-matched cancer-free controls, derived from English primary care data linked to cancer registrations, hospital admissions and death registrations. Comorbidity prevalences were calculated 1 and 5 years from cancer diagnosis. Risk of hospitalisation or death due to influenza was compared using Cox models adjusted for baseline demographics and comorbidities. FINDINGS: 108,215 cancer survivors and 523,541 cancer-free controls were included. Cancer survivors had more diabetes, asthma, other respiratory, cardiac, neurological, renal, and liver diseases, and less obesity, compared with controls, but there was variation by cancer site. There were 205 influenza hospitalisations/deaths, with cancer survivors at higher risk than controls (adjusted HR 2.78, 95% CI 2.04-3.80). Haematological cancer survivors had large elevated risks persisting for >10 years (HR overall 15.17, 7.84-29.35; HR >10 years from cancer diagnosis 10.06, 2.47-40.93). Survivors of other cancers had evidence of raised risk up to 5 years from cancer diagnosis only (HR >5 years 2.22, 1.31-3.74). INTERPRETATION: Risks of severe COVID-19 outcomes are likely to be elevated in cancer survivors. This should be taken into account in policies targeted at clinical risk groups, and vaccination for both influenza, and, when available, COVID-19, should be encouraged in cancer survivors.
Authors: Phillip S Blanchette; Hannah Chung; Kathleen I Pritchard; Craig C Earle; Michael A Campitelli; Sarah A Buchan; Kevin L Schwartz; Natasha S Crowcroft; Jonathan B Gubbay; Timothy Karnauchow; Kevin Katz; Allison J McGeer; James D McNally; David C Richardson; Susan E Richardson; Laura C Rosella; Andrew Simor; Marek Smieja; George Zahariadis; Aaron Campigotto; Jeffrey C Kwong Journal: J Clin Oncol Date: 2019-08-29 Impact factor: 44.544
Authors: Lennard Yw Lee; Jean-Baptiste Cazier; Vasileios Angelis; Roland Arnold; Vartika Bisht; Naomi A Campton; Julia Chackathayil; Vinton Wt Cheng; Helen M Curley; Matthew W Fittall; Luke Freeman-Mills; Spyridon Gennatas; Anshita Goel; Simon Hartley; Daniel J Hughes; David Kerr; Alvin Jx Lee; Rebecca J Lee; Sophie E McGrath; Christopher P Middleton; Nirupa Murugaesu; Thomas Newsom-Davis; Alicia Fc Okines; Anna C Olsson-Brown; Claire Palles; Yi Pan; Ruth Pettengell; Thomas Powles; Emily A Protheroe; Karin Purshouse; Archana Sharma-Oates; Shivan Sivakumar; Ashley J Smith; Thomas Starkey; Chris D Turnbull; Csilla Várnai; Nadia Yousaf; Rachel Kerr; Gary Middleton Journal: Lancet Date: 2020-05-28 Impact factor: 79.321
Authors: Rashmi Verma; Ruth E Foster; Kieran Horgan; Katherine Mounsey; Helen Nixon; Natuley Smalle; Thomas A Hughes; Clive R D Carter Journal: Breast Cancer Res Date: 2016-01-26 Impact factor: 6.466
Authors: Rocco Servidio; Antonio Malvaso; Deborah Vizza; Moira Valente; Maria Rosita Campagna; Melania Lo Iacono; Leslie R Martin; Francesco Bruno Journal: Support Care Cancer Date: 2022-06-25 Impact factor: 3.359
Authors: Krishnan Bhaskaran; Sebastian Bacon; Stephen Jw Evans; Chris J Bates; Christopher T Rentsch; Brian MacKenna; Laurie Tomlinson; Alex J Walker; Anna Schultze; Caroline E Morton; Daniel Grint; Amir Mehrkar; Rosalind M Eggo; Peter Inglesby; Ian J Douglas; Helen I McDonald; Jonathan Cockburn; Elizabeth J Williamson; David Evans; Helen J Curtis; William J Hulme; John Parry; Frank Hester; Sam Harper; David Spiegelhalter; Liam Smeeth; Ben Goldacre Journal: Lancet Reg Health Eur Date: 2021-05-08
Authors: Elena Roel; Andrea Pistillo; Martina Recalde; Sergio Fernández-Bertolín; María Aragón; Isabelle Soerjomataram; Mazda Jenab; Diana Puente; Daniel Prieto-Alhambra; Edward Burn; Talita Duarte-Salles Journal: Int J Cancer Date: 2021-11-03 Impact factor: 7.316